Brain tumour clinical trial title

MOLGEN – Molecular Genetics of Adverse Drug Reactions (Study ID: 8630)

Brain tumour type

Schwannoma,  Pituitary,  Brain metastases,  Neuroblastoma,  oligoastrocytoma,  Ependymoma,  Meningioma,  Medulloblastoma,  Glioma,  Glioblastoma,  Astrocytoma,  Anaplastic oligodendroglioma,  Anaplastic glioma,  Anaplastic astrocytoma, 



Adverse drug reactions (ADR's) are a common cause of drug-related morbidity and may account for about 6.5% of all hospital admissions. A meta-analysis of studies performed in the USA has shown that ADRs may be the fourth commonest cause of death. ADRs are also a significant impediment to drug development, and a significant cause of drug withdrawal. The purpose of this research is to (a) identify patients with different types of adverse drug reactions; (b) using DNA obtained from blood or Saliva samples from these patients, identify genetic factors which predispose to adverse reactions. The net effect of our research will be the development of genetic tests which can help in predicting individual susceptibility to adverse reactions prior to the medication's administration. Patients with a pre-disposition to reacting adversely can be prescribed alternative medication of monitored more closely during their treatment. This will reduce the harm for patients and save valuable resources for the NHS. We aim to recruit 250 cases for each reaction for a period of eight years throughout multiple sites in the UK. Specific adverse drug reactions we are looking at include: - Statin induced myotoxicity, characterised by high CK - Severe hypersensitivity reactions including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis - Anaphylaxis induced by NMBA anaesthetics - ACE inhibitor or ARB induced angioedema - Taxane hypersensitivity - Chemotherapy induced peripheral neuropathy - Bleomycin induced lung toxicity - Clozipine induced agranulocytosis or neutropenia - Bisphosphonate-related osteonecrosis of the jaw - Tenofovir associated renal injury - Serious bleeds induced by warfarin or other anticoagulants

Date added: 12th January 2019

Open/Closed: Open

Trial ends: February 2019


University of Liverpool

Contact details

Mrs Anita Hanson :
Crown Street

L69 3BX

Find on Google maps »